Mitsubishi Chemical inks $4.3B Tanabe buyout

Mitsubishi Chemical Holdings is buying Tanabe Seiyaku for $4.3 billion in a deal that will double its drug sales. Analysts note that the combined company--which will create the fifth largest pharma company in Japan--will still be small by global pharma standards, but that the drug industry in Japan is under considerable pressure to consolidate as price controls in the country squeeze margins. The consolidation is intended to make them more competitive outside of Japan, a strategy that is seen as crucial to their long-term viability. Tanabe's best-selling drug is Remicade.

- here's the release on the deal

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.